Shanghai RAAS Blood Products Co Ltd SZSE:002252:
2025 NET PROFIT DOWN 28.1%
Shanghai RAAS Blood Products 2025 Net Profit Down 28.1%
Earlier from Shanghai Raas Blood Products Co., Ltd. Class A
- Shanghai RAAS Blood Products: Net profit dropped 26% on flat revenue, with major buybacks and clinical trial advances
- Shanghai RAAS Blood Products Q3 Net Profit Down 26.2% Y/Y
- Shanghai RAAS Blood Products: Revenue and profit fell, but cash flow and strategic expansion strengthened future prospects
- Shanghai RAAS Blood Products: Net profit fell 25% in Q1 2025, but strategic acquisitions and buybacks support future growth